Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.

Autor:	Najminejad Z; Department of Internal Medicine, School of Medicine, Kerman University of Medical Sciences, Kerman 7616913355, Iran., Dehghani F; Student Research Committee, Larestan University of Medical Sciences, Larestan 7431895639, Iran., Mirzaei Y; Department of Medical Biochemical Analysis, Cihan University-Erbil, Kurdistan Region, Erbil 44001, Iraq., Mer AH; Department of Nursing, Mergasour Technical Institute, Erbil Polytechnic University, Erbil 44001, Iraq., Saghi SA; Student Research Committee, Larestan University of Medical Sciences, Larestan 7431895639, Iran., Abdolvahab MH; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran 1517964311, Iran., Bagheri N; Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord 8813733450, Iran., Meyfour A; Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran 1985717413, Iran., Jafari A; ATMP Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran 1517964311, Iran., Jahandideh S; Department of Research and Development, Orchidgene co, Tehran 1387837584, Iran., Gharibi T; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 5165665931, Iran., Amirkhani Z; Student Research Committee, Larestan University of Medical Sciences, Larestan 7431895639, Iran., Delam H; Student Research Committee, Larestan University of Medical Sciences, Larestan 7431895639, Iran., Mashatan N; Graduated, School of Applied Sciences, University of Brighton, Brighton BN2 4GJ, UK. Electronic address: n.mashatan1@uni.brighton.ac.uk., Shahsavarani H; Department of Cell and Molecular Biology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran 1983963113, Iran. Electronic address: hosein.shahsavarani@gmail.com., Abdollahpour-Alitappeh M; Cellular and Molecular Biology Research Center, Larestan University of Medical Sciences, Larestan 7431895639, Iran. Electronic address: abdollahpour1983@yahoo.com.
Jazyk:	angličtina
Zdroj:	Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2023 Jul 05; Vol. 31 (7), pp. 1874-1903. Date of Electronic Publication: 2023 Mar 22.
DOI:	10.1016/j.ymthe.2023.03.019
Abstrakt:	Antibody-drug conjugates (ADCs) are a promising class of cancer biopharmaceuticals that exploit the specificity of a monoclonal antibody (mAb) to selectively deliver highly cytotoxic small molecules to targeted cancer cells, leading to an enhanced therapeutic index through increased antitumor activity and decreased off-target toxicity. ADCs hold great promise for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after the approval and tremendous success of trastuzumab emtansine and trastuzumab deruxtecan, representing a turning point in both HER2-positive breast cancer treatment and ADC technology. Additionally and importantly, a total of 29 ADC candidates are now being investigated in different stages of clinical development for the treatment of HER2-positive breast cancer. The purpose of this review is to provide an insight into the ADC field in cancer treatment and present a comprehensive overview of ADCs approved or under clinical investigation for the treatment of HER2-positive breast cancer. Competing Interests: Declaration of interests The authors declare no competing interests. (Copyright © 2023 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu